undamentalytics Newsletter
Sign in

Compugen LTD (CGEN) stock

Add to watchlist

Add holding +

NASDAQ: CGEN Nasdaq Biotechnology Next results ~November 9, 2026

A Fundamentals grade

Compugen LTD is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($7.89) is 3.92x the share price ($2.01) and 3.03x the median of our other models ($2.60); the other models don't support a gap this wide.

Price vs value

Under review: our cash-flow value ($7.89) is 3.92x the share price ($2.01) and 3.03x the median of our other models ($2.60); the other models don't support a gap this wide. We'll show the comparison once resolved.

Compugen LTD valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 12 sales by directors and officers, last 12 monthsInsider trades
  • Funds29 adding, 31 cuttingOf 14 active managers that changed their stake, 7 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Compugen files

Where Compugen LTD stands after its latest Filing

Revenue for the twelve months was $73m, up 161.1% on a year earlier, against a decline of 16.7% a quarter earlier. Free-cash-flow margin rose to 43.1% from -383.1% a year earlier. Operating margin widened to 43.1% from -584.6%. The diluted share count is up 4.8% on a year earlier, which dilutes existing holders. It passes 1 of our 1 financial-health checks.

Our model value for Compugen is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Compugen LTD's trailing-twelve-month revenue grew 161.1% year on year, with a free-cash-flow margin of 43.1%. Where it stands out: net margin of 48.6% ranks 6 of 180 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$7.9 per share in the base case (~$6.3–$9.9 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Net margin expanding: TTM net margin reached 48.6%, up 99.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 161.1% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 177.9 points higher than a quarter earlier.
  • High operating margin. 43.1% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 96.5 points on a year ago.
  • Strong cash generation. 43.1% of revenue turned into free cash flow, against a median of -145.4% for biotechnology companies we cover.

Things to watch

  • Share dilution. Diluted shares rose 4.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 64% and a beta of 1.6 against the S&P 500.

Latest results

Earnings per share
-$0.07 against an average estimate of -$0.09: beat by 17.6%
Next report
November 9, 2026; average EPS estimate -$0.09

Compugen's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week+5.3%
  • 1 month-14.3%
  • This year+29.4%
  • 1 year+11.9%
  • 5 years-70.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$72.8M
Operating margin
43.1%
Net margin
48.6%
EPS (TTM, diluted)
$0.38

Growth

Revenue growth
+161.1%
Change in growth rate
+177.9 pts
Share count change
+4.8%

Cash

Free cash flow (TTM)
$31.3M
FCF margin
43.1%
Stock pay % of revenue
2.6%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for CGEN from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Compugen LTD valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($7.89) is 3.92x the share price ($2.01) and 3.03x the median of our other models ($2.60); the other models don't support a gap this wide.

Our value per share comes from a discounted-cash-flow model of Compugen LTD's free cash flow after stock-based pay ( $19.7M, FY2025 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Compugen LTD as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.18 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$7.9 ~$6.3–$9.9 Primary model, counts double
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.6 ~$1.6–$1.7 Included
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$3.6 ~$3.1–$7.9 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Compugen LTD with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201520162018202020212022202320242025
Share price$6.39$5.10$2.17$12.11$4.30$0.72$1.98$1.53$1.53
Market value$322m$259m$120m$964m$362m$62m$174m$137m$144m
+ Net debt (− = net cash)−$11m−$10m−$6m−$7m−$8m−$11m−$14m−$18m−$91m
Enterprise value$312m$250m$114m$957m$354m$51m$160m$119m$53m
Multiples
Price / sales 34.7xn/m6.7xn/m60.3x8.3x5.2x4.9x2.0x
Price / earnings ————————4.1x
Price / free cash flow ———————2.8x4.6x
EV / EBITDA ————————1.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $975000 and EPS of −$0.09 (range −$0.10 to −$0.07) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.33 −187% $9m −87%
Next −$0.37 −11% $8m −16%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.9% on 90 days ago. In the last 30 days, 1 analyst raised Compugen LTD's forecast and 0 cut it.

Consensus EPS forecast Compugen LTD, last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.34 Current fiscal year, 60 days ago: −$0.33 Current fiscal year, 30 days ago: −$0.33 Current fiscal year, 7 days ago: −$0.33 Current fiscal year, Now: −$0.33 −$0.33 Next fiscal year, 90 days ago: −$0.36 Next fiscal year, 60 days ago: −$0.36 Next fiscal year, 30 days ago: −$0.37 Next fiscal year, 7 days ago: −$0.37 Next fiscal year, Now: −$0.37 −$0.37

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.34−$0.36
60 days ago −$0.33−$0.36
30 days ago −$0.33−$0.37
7 days ago −$0.33−$0.37
Now −$0.33−$0.37

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.09 −$0.07 +17.6%
Mar 2026 −$0.08 −$0.08 0.0%
Dec 2025 $0.14 $0.60 +339.0%
Sept 2025 −$0.09 −$0.07 +22.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202655
  3. Aug 202655

Counts of recommendations published by analysts covering Compugen LTD, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.7%
of tradable shares
Days to cover
13.9
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
15%
of shares
Held by insiders
0.4%
of shares
Employees
75
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CGEN−65%−83%+175%−23%0%+29%
Industry peers (median)−35%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CGEN42%25%42%42%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CGEN−70%−88%−62%−52%−54%−39%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 97% from August 25, 2020 to November 13, 2023. Getting back needed a 3570% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.47 – $3.10
From 52-week high
−36.1%
vs 50-day average
−14.3%
vs 200-day average
−13.8%
Volatility (1 year)
64%
Beta vs S&P 500
1.58

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Compugen LTD in five measures

Fundamentals grade A
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Compugen LTD
$0 $20M $40M $60M $80M FY12 Q4 FY15 Q4 FY20 Q4 FY25 Q4 Revenue (TTM), FY12 Q4: $242K Revenue (TTM), FY13 Q4: $3.5M Revenue (TTM), FY14 Q4: $12.4M Revenue (TTM), FY15 Q4: $9.3M Revenue (TTM), FY16 Q4: $712K Revenue (TTM), FY18 Q4: $17.8M Revenue (TTM), FY20 Q4: $2M Revenue (TTM), FY21 Q4: $6M Revenue (TTM), FY22 Q4: $7.5M Revenue (TTM), FY23 Q4: $33.5M Revenue (TTM), FY24 Q4: $27.9M Revenue (TTM), FY25 Q4: $72.8M $72.8M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY12 Q4 $242K
FY13 Q4 $3.5M
FY14 Q4 $12.4M
FY15 Q4 $9.3M
FY16 Q4 $712K
FY18 Q4 $17.8M
FY20 Q4 $2M
FY21 Q4 $6M
FY22 Q4 $7.5M
FY23 Q4 $33.5M
FY24 Q4 $27.9M
FY25 Q4 $72.8M
Revenue growth, TTM YoY Compugen LTD
-500% 0% 500% 1000% 1500% FY10 Q4 FY14 Q4 FY16 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY10 Q4: 346.0% Revenue growth, TTM YoY, FY13 Q4: 1366.5% Revenue growth, TTM YoY, FY14 Q4: 248.5% Revenue growth, TTM YoY, FY15 Q4: -25.0% Revenue growth, TTM YoY, FY16 Q4: -92.3% Revenue growth, TTM YoY, FY21 Q4: 200.0% Revenue growth, TTM YoY, FY22 Q4: 25.0% Revenue growth, TTM YoY, FY23 Q4: 346.1% Revenue growth, TTM YoY, FY24 Q4: -16.7% Revenue growth, TTM YoY, FY25 Q4: 161.1% 161.1%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY10 Q4 346.0%
FY13 Q4 1366.5%
FY14 Q4 248.5%
FY15 Q4 -25.0%
FY16 Q4 -92.3%
FY21 Q4 200.0%
FY22 Q4 25.0%
FY23 Q4 346.1%
FY24 Q4 -16.7%
FY25 Q4 161.1%
Operating margin (TTM) Compugen LTD
-6000% -4000% -2000% 0% 2000% FY12 Q4 FY15 Q4 FY20 Q4 FY25 Q4 Operating margin (TTM), FY12 Q4: -5595.9% Operating margin (TTM), FY13 Q4: -480.2% Operating margin (TTM), FY14 Q4: -99.8% Operating margin (TTM), FY15 Q4: -225.5% Operating margin (TTM), FY16 Q4: -4576.3% Operating margin (TTM), FY18 Q4: -130.5% Operating margin (TTM), FY20 Q4: -1574.8% Operating margin (TTM), FY21 Q4: -584.6% Operating margin (TTM), FY22 Q4: -471.7% Operating margin (TTM), FY23 Q4: -38.8% Operating margin (TTM), FY24 Q4: -53.4% Operating margin (TTM), FY25 Q4: 43.1% 43.1%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY12 Q4 -5595.9%
FY13 Q4 -480.2%
FY14 Q4 -99.8%
FY15 Q4 -225.5%
FY16 Q4 -4576.3%
FY18 Q4 -130.5%
FY20 Q4 -1574.8%
FY21 Q4 -584.6%
FY22 Q4 -471.7%
FY23 Q4 -38.8%
FY24 Q4 -53.4%
FY25 Q4 43.1%
FCF margin (TTM) Compugen LTD
-6000% -4000% -2000% 0% 2000% FY12 Q4 FY15 Q4 FY20 Q4 FY25 Q4 FCF margin (TTM), FY12 Q4: -4897.1% FCF margin (TTM), FY13 Q4: -190.7% FCF margin (TTM), FY14 Q4: -105.5% FCF margin (TTM), FY15 Q4: -309.7% FCF margin (TTM), FY16 Q4: -3148.6% FCF margin (TTM), FY18 Q4: -75.6% FCF margin (TTM), FY20 Q4: -1424.3% FCF margin (TTM), FY21 Q4: -383.1% FCF margin (TTM), FY22 Q4: -461.2% FCF margin (TTM), FY23 Q4: -107.8% FCF margin (TTM), FY24 Q4: 177.6% FCF margin (TTM), FY25 Q4: 43.1% 43.1%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY12 Q4 -4897.1%
FY13 Q4 -190.7%
FY14 Q4 -105.5%
FY15 Q4 -309.7%
FY16 Q4 -3148.6%
FY18 Q4 -75.6%
FY20 Q4 -1424.3%
FY21 Q4 -383.1%
FY22 Q4 -461.2%
FY23 Q4 -107.8%
FY24 Q4 177.6%
FY25 Q4 43.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Compugen took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $72.8M
  2. Other income $4.1M · 5.6%
  3. Cost of revenue $9.3M · 12.7%
  4. Gross profit $63.5M · 87.3%
  5. Research and development $22.8M · 31.3%
  6. Selling, general and admin $8.9M · 12.2%
  7. Other operating costs $539,000 · 0.7%
  8. Operating income $31.3M · 43.1%
  9. Net income $35.3M · 48.6%

Shares of revenue. Source: Compugen's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2018 Dec 2018 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 1 0 4 12 9 1 18 2 6 8 33 28 73
Gross profit 0 1 0 1 9 8 0 17 2 5 7 31 20 64
EBITDA −7 −8 −13 −17 −12 −20 −31 −22 −31 −35 −35 −13 −14 32
Operating income −8 −8 −14 −17 −12 −21 −33 −23 −31 −35 −35 −13 −15 31
Net income −4 −7 −14 −14 −11 −20 −32 −23 −30 −34 −34 −19 −14 35
Diluted EPS −$0.13 −$0.22 −$0.38 −$0.36 −$0.26 −$0.40 −$0.62 −$0.41 −$0.37 −$0.41 −$0.39 −$0.21 −$0.16 $0.38
Growth (year on year)
Revenue — +346.0% −78.3% +>999% +248.5% −25.0% −92.3% +>999% −88.8% +200.0% +25.0% +346.1% −16.7% +161.1%
Margins
Gross margin 100.0% 79.9% 16.9% 29.3% 73.0% 82.4% 68.7% 94.2% 97.0% 88.7% 87.0% 94.0% 71.5% 87.3%
EBITDA margin <−999% −688.5% <−999% −469.8% −94.4% −213.6% <−999% −122.7% <−999% −576.9% −465.2% −37.4% −51.7% 43.7%
Operating margin <−999% −706.5% <−999% −480.2% −99.8% −225.5% <−999% −130.5% <−999% −584.6% −471.7% −38.8% −53.4% 43.1%
Net margin <−999% −646.0% <−999% −396.8% −89.7% −217.3% <−999% −127.0% <−999% −570.0% −449.3% −56.1% −51.1% 48.6%
Free-cash-flow margin <−999% −387.9% <−999% −190.7% −105.5% −309.7% <−999% −75.6% <−999% −383.1% −461.2% −107.8% 177.6% 43.1%
Cash flow
Cash from operations −7 −4 −11 −6 −11 −26 −20 −13 −28 −23 −34 −36 50 32
Capital spending 0 0 1 0 2 3 3 0 0 0 0 0 0 0
Free cash flow −8 −4 −12 −7 −13 −29 −22 −13 −28 −23 −35 −36 49 31
Stock-based pay 2 2 2 4 4 4 3 2 3 4 4 4 3 2
Free cash flow after stock pay −9 −7 −14 −10 −17 −33 −26 −16 −31 −27 −39 −40 46 29
Balance sheet
Cash 15 7 16 29 26 11 10 6 7 8 11 14 18 91
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −15 −7 −16 −29 −26 −11 −10 −6 −7 −8 −11 −14 −18 −91
Diluted shares — 33m 36m 39m 48m 50m 51m 55m 80m 84m 87m 88m 90m 94m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 1 checks passed · December 31, 2025
What it owns · $157m
Short-term assets $148mLonger-term assets $9m
What it owes, and who funded it · $125m
Short-term liabilities $23mShareholders' equity $103m
  • Short-term assets cover short-term liabilities $148m of assets due within a year against $23m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Compugen LTD's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.8%
year over year
R&D spending
31.3%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CGEN VRDN WVE ASMB RXRX CYTK Median
Revenue, last 12 months $73m $71m $71m $75m $68m $68m $56m
Revenue growth, last 12 months 161.1% >999% 202.3% 125.1% 56.2% −21.1% 12.6%
Revenue growth, 3-year average 302.6% 264.4% 20.7% −3.3% 12.9% 89.5% 13.7%
Revenue growth, latest quarter — 278.7% 72.9% 38.9% 258.5% −57.1% 10.2%
Gross margin 87.3% 54.5% — — 29.2% — 82.9%
Operating margin 43.1% −569.7% −320.9% −11.8% −725.4% <−999% −189.4%
Operating margin, 3-year average −255.7% <−999% −256.4% −126.0% −995.4% <−999% −363.5%
Net margin 48.6% −544.1% −296.9% −0.1% −697.1% <−999% −169.8%
Cash from operations / revenue 43.5% −468.7% −291.9% −51.4% −455.1% −820.8% −168.0%
Free-cash-flow margin 43.1% −471.0% −293.8% −51.5% −458.0% −858.2% −162.4%
Free-cash-flow margin, 3-year average −216.6% <−999% −148.0% −35.8% −664.1% <−999% −310.0%
Stock pay / revenue 2.6% 75.4% 52.8% 8.9% 129.4% 188.1% 20.0%
Change in share count 4.8% 42.0% 20.2% 50.8% 32.7% 4.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 161.1% 12.6% 28 of 172
Change in growth rate Growth +177.9pp -0.1pp 14 of 172
Gross margin Profitability 87.3% 82.4% 27 of 75
Operating margin Profitability 43.1% -189.4% 9 of 175
Net margin Profitability 48.6% -157.3% 6 of 180
Free-cash-flow margin Cash generation 43.1% -145.4% 9 of 176
Stock pay as % of revenue Cash generation 2.6% 19.2% 15 of 179
Change in share count Balance sheet 4.8% 7.9% 65 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$30.2M
Institutions reporting
82
Shares held vs prior quarter
▼ 0.5%
Positions opened / closed
15 / 11

Top buyers and sellers, Q2 2026: 29 institutions bought and 31 sold ; the biggest buyer was Altshuler Shaham Ltd (+518K shares) and the biggest seller Northern Trust Corp (−651K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Silverarc Capital Management, LLC $6.8M 3.2M 22.5% ▼ 4.0%
Renaissance Technologies LLC $4M 1.9M 13.3% ▲ 15.0%
Morgan Stanley $2.3M 1.1M 7.4% ▼ 0.1%
Nomura Asset Management International Inc. $2.2M 1.0M 7.2% 0.0%
Taylor Frigon Capital Management LLC $1.8M 842K 6.0% ▼ 0.7%
ARK Investment Management LLC $1.7M 787K 5.6% ▼ 25.1%
Altshuler Shaham Ltd $1.1M 522K 3.7% ▲ 12940.6%
Two Sigma Investments, LP $1.1M 512K 3.6% ▼ 1.8%
State Street Corp $889,530 416K 2.9% ▲ 0.1%
Atom Investors LP $649,546 304K 2.1% ▲ 569.0%
Yelin Lapidot Holdings Management Ltd. $603,444 282K 2.0% ▼ 11.6%
UBS Group AG $589,942 276K 2.0% ▼ 10.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Compugen LTD's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $126,301 12 trades by 2 insiders · 100% under pre-set plans
Net ▼ $126,301 net selling
Insider Date Trade Shares Price Value
Levine Zurit SVP, Business Development July 9, 2026 Sell pre-set plan 1,875 $2.50 $4,688
Ophir Eran President and CEO April 24, 2026 Sell pre-set plan 5,000 $3.20 $16,000
Levine Zurit SVP, Business Development April 24, 2026 Sell pre-set plan 2,000 $3.20 $6,400
Levine Zurit SVP, Business Development April 14, 2026 Sell pre-set plan 2,000 $2.80 $5,600
Ophir Eran President and CEO April 14, 2026 Sell pre-set plan 5,000 $2.90 $14,500
Levine Zurit SVP, Business Development April 10, 2026 Sell pre-set plan 3,125 $2.56 $8,000
Levine Zurit SVP, Business Development April 10, 2026 Sell pre-set plan 3,125 $2.56 $8,000
Levine Zurit SVP, Business Development April 8, 2026 Sell pre-set plan 5,375 $2.42 $13,008
Levine Zurit SVP, Business Development April 7, 2026 Sell pre-set plan 2,500 $2.30 $5,750
Ophir Eran President and CEO April 1, 2026 Sell pre-set plan 5,625 $2.21 $12,431
Levine Zurit SVP, Business Development April 1, 2026 Sell pre-set plan 3,500 $2.20 $7,700
Levine Zurit SVP, Business Development March 26, 2026 Sell pre-set plan 11,875 $2.04 $24,225

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Compugen LTD was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Compugen LTD in brief

What does Compugen LTD do?
Compugen LTD is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Compugen LTD's stock ticker?
Compugen LTD trades under the ticker CGEN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Compugen LTD's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Compugen LTD reported revenue of $72.8M, 161.1% higher than a year earlier, according to its SEC filings.
What is Compugen LTD's free cash flow?
Compugen LTD's free-cash-flow margin is 43.1% of revenue over the trailing twelve months, ranking 9 of the 176 biotechnology companies we cover.
Who are Compugen LTD's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Silverarc Capital Management, LLC, Renaissance Technologies LLC and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Compugen LTD's market cap?
On December 31, 2025, Compugen LTD's market capitalisation was about $144M, with a price-to-earnings ratio of 4.1 and net debt of -$90.6M. Market figures come from third-party market data and may be delayed.
Who are Compugen LTD's competitors?
In our Biotechnology peer group, the companies closest to Compugen LTD are Viridian Therapeutics, Inc.\de, Wave Life Sciences, Inc., Assembly Biosciences, Inc., Recursion Pharmaceuticals, Inc. and Cytokinetics Inc. The side-by-side comparison below sets their revenue, margins and growth against Compugen LTD's.
Are insiders buying or selling Compugen LTD stock?
Over the last 12 months, Compugen LTD's directors and officers reported 0 open-market purchases and 12 sales on Form 4. The insider trading page charts every trade.
When is Compugen LTD's next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Compugen LTD announces its own schedule.